Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40JMN | ISIN: US17248W3034 | Ticker-Symbol:
NASDAQ
04.06.25 | 21:58
4,220 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CINGULATE INC Chart 1 Jahr
5-Tage-Chart
CINGULATE INC 5-Tage-Chart

Aktuelle News zur CINGULATE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.05.Cingulate Reports Details Of Pre-NDA Minutes For CTx-1301; NDA Submission Planned For Summer3
09.05.Cingulate reports Q1 results4
CINGULATE Aktie jetzt für 0€ handeln
08.05.Cingulate Inc. Q1 Loss Misses Estimates2
08.05.Cingulate Inc. - 10-Q, Quarterly Report2
08.05.Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets67Pre-NDA Meeting for CTx-1301(dexmethylphenidate) Held April 2, 2025; New Drug Application Submission Targeted for Mid-2025 Non-Dilutive Funding to Accelerate Development of CTx-2103 (buspirone) KANSAS...
► Artikel lesen
08.05.Cingulate Inc. - 8-K, Current Report1
10.04.Cingulate secures $3m to advance once-daily anxiety treatment3
09.04.Cingulate Inc. - 8-K, Current Report2
09.04.Cingulate Inc.: Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)4
03.04.Cingulate Inc.: Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-13013
27.03.Cingulate Inc. - 10-K, Annual Report4
26.03.Cingulate reports FY results4
26.03.Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved243In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025$17.5 million increase in Working Capital; Cash Runway Extending into Q4, Well Beyond Target Date...
► Artikel lesen
26.03.Cingulate Inc. - 8-K, Current Report4
04.03.Cingulate Inc.: Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025150Results Have Been Submitted Ahead of In-Person Meeting with FDA Set for April 2 CTx-1301 is the First, True, Once-Daily Stimulant Medication to Treat ADHD Over the Entire Active Day KANSAS CITY...
► Artikel lesen
04.03.Cingulate Inc. - 8-K, Current Report-
03.02.Cingulate Inc. - 8-K, Current Report1
24.01.Cingulate Inc. - 8-K, Current Report5
07.01.Cingulate Inc. - 8-K, Current Report5
23.12.24Cingulate Inc.: Cingulate Completes Financing Transaction for Net Proceeds of $5,000,0006
Seite:  Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1